Global Continuous Glucose Monitoring Systems Market Size By Type (Wearable, Implantable), By Application (Child, Adult), By Region, And Segment Forecasts, 2023 to 2032

The Global Continuous Glucose Monitoring (CGM) Systems Market was valued at USD 8.6 billion in 2023 and is projected to surpass USD 25.7 billion by 2031, growing at a CAGR of 14.9% during the forecast period from 2023 to 2031. This rapid expansion is fueled by the rising global prevalence of diabetes, increasing awareness about glycemic management, and technological advancements in wearable health monitoring devices. CGM systems provide real-time glucose level insights, empowering both patients and healthcare providers with better data for diabetes management, significantly reducing the risk of long-term complications.

Drivers:

Rising Global Diabetes Incidence:

The escalating number of people diagnosed with diabetes globally, particularly Type 1 and insulin-dependent Type 2 diabetes, is a critical driver of the CGM systems market. Early and consistent glucose monitoring helps mitigate complications, supporting the adoption of continuous monitoring over traditional blood glucose testing.

Technological Advancements in Sensors and Wearables:

Ongoing innovation has led to the development of minimally invasive and non-invasive sensors, smartphone connectivity, predictive analytics, and improved accuracy. These improvements are making CGM systems more user-friendly and acceptable among diverse patient populations.

Growing Shift Towards Preventive Healthcare:

Healthcare systems globally are moving towards preventive care. CGM systems play a vital role in proactive diabetes management, offering actionable insights for lifestyle and medication adjustments in real time.

Restraints:

High Cost of Devices and Limited Reimbursement:

Despite clinical benefits, the high upfront and maintenance costs of CGM systems, combined with inconsistent insurance reimbursement policies, pose significant barriers, particularly in low-income and developing regions.

User Compliance and Technical Challenges:

Continuous use of wearable devices may lead to skin irritation, sensor adhesion issues, or device fatigue. Additionally, false alerts or calibration requirements can affect user experience and long-term compliance.

Opportunity:

Integration with Digital Health Ecosystems:

The growing ecosystem of digital health, including telemedicine platforms, electronic health records, and AI-driven analytics, presents a significant opportunity for CGM system integration. This convergence can enhance real-time monitoring, patient engagement, and clinical decision-making.

Emerging Markets Expansion:

Rapid urbanization, increasing healthcare spending, and growing diabetes awareness in emerging economies such as India, China, Brazil, and Southeast Asia provide ample opportunities for CGM manufacturers to tap into underserved diabetic populations.

Market by System Type Insights:

The market is segmented by system types into Real-time CGM (rtCGM) and Intermittently Scanned CGM (isCGM). The Real-time CGM segment dominated in 2023, driven by its continuous feedback mechanism and compatibility with insulin pumps and AI tools for predictive alerts. rtCGMs are preferred in clinical settings for their higher accuracy and advanced data sharing capabilities. However, the isCGM segment is witnessing faster adoption due to its affordability and ease of use among non-insulin-dependent patients.

Market by End-use Insights:

Based on end use, Hospitals & Clinics accounted for the largest market share in 2023, owing to increased CGM adoption for inpatient diabetes care and critical care monitoring. Meanwhile, the Homecare segment is expected to witness the highest growth rate during the forecast period, supported by the rise in remote monitoring technologies and patient preference for personalized care.

Market by Regional Insights:

North America held the largest market share in 2023 due to high diabetes prevalence, favorable reimbursement frameworks, and strong presence of key industry players. Europe follows closely, supported by advanced healthcare infrastructure and growing investment in chronic disease management. The Asia-Pacific region is projected to exhibit the fastest CAGR during the forecast period, fueled by healthcare modernization, rising awareness, and favorable government initiatives across populous nations like China and India.

Competitive Scenario:

Key players in the global CGM systems market include Abbott Laboratories, Dexcom, Inc., Medtronic plc, Senseonics Holdings, Inc., and Roche Diabetes Care. These companies are actively pursuing product innovation, strategic partnerships, and global expansion to capture market share. For instance:

In 2023, Abbott received FDA approval for its FreeStyle Libre 3 system featuring real-time connectivity and longer sensor wear duration.

Dexcom launched its G7 system with a smaller form factor and faster warm-up time in 2024 across key global markets.

Senseonics expanded its implantable CGM offerings by increasing sensor wear duration to 180 days in Europe and the U.S.

Scope of Work – Global Continuous Glucose Monitoring Systems Market

Report Metric Details

Market Size (2023) USD 8.6 billion

Projected Market Size (2031) USD 25.7 billion

CAGR (2023–2031) 14.9%

Market Segments By System Type (rtCGM, isCGM), End-use, Region

Growth Drivers Rising diabetes prevalence, tech advancement, preventive healthcare focus

Opportunities Integration with digital health, expansion in emerging markets

Key Market Developments:

2023: Abbott launched FreeStyle Libre 3 in the U.S. with full smartphone integration and real-time alerts.

2024: Dexcom received regulatory approval for its G7 system across Europe and Japan.

2025: Medtronic announced a partnership with major hospital networks to pilot AI-integrated CGM platforms.

FAQs:

What is the current market size of the Global Continuous Glucose Monitoring Systems Market?

The market was valued at USD 8.6 billion in 2023.

What is the major growth driver of the Global Continuous Glucose Monitoring Systems Market?

Rising prevalence of diabetes and increasing adoption of wearable glucose monitoring technologies.

Which is the largest region during the forecast period in the Global Continuous Glucose Monitoring Systems Market?

North America holds the largest share due to advanced infrastructure and supportive reimbursement policies.

Which segment accounted for the largest market share in the Global Continuous Glucose Monitoring Systems Market?

The Real-time CGM (rtCGM) segment led the market in 2023.

Who are the key market players in the Global Continuous Glucose Monitoring Systems Market?

Abbott Laboratories, Dexcom, Inc., Medtronic plc, Senseonics Holdings, Inc., and Roche Diabetes Care.